The University at Buffalo's Department of Neurology and the Jacobs Neurological Institute received approval to enroll patients in a clinical trial of desmosteplase, a drug candidate for acute ischemic stroke that was derived from a bioengineered protein in vampire bats' saliva. The study is part of a worldwide trial spearheaded by Lundbeck.

Related Summaries